Human health

Overview
Right now, our human health project pipeline is focused on tackling two significant health challenges of our time – antimicrobial resistance and diseases affecting weight management and liver health.

Respiratory Infections in Cystic Fibrosis
Neem’s lead candidate NX-AS-401 is a potential new treatment for chronic respiratory infections in patients with Cystic Fibrosis. It is designed to help eradicate the Pseudomonas bacteria, which cause the lung infections that are the key source of morbidity and mortality for cystic fibrosis patients.

NX-AS-401 is a quorum sensing inhibitor. It disrupts communication between bacteria, thereby preventing them from forming the film that is crucial in protecting them from current anti-Pseudomonal antibiotics.

Neem’s NX-AS-401 is expected to commence human clinical trials in 2017.

Infection Control in Wounds
Chronic wounds, or those that fail to heal within 12 weeks, are costly both for individuals and societies. This is because of the vicious circle of inflammation, infection and subsequent failure to heal that becomes active when a wound becomes chronic.

Treatment of the direct effects and complications of these wounds accounts for about 3% the NHS’s annual budget. This translates to at least £5000 per patient per year. In Europe, it is estimated that about 4% of the annual healthcare budget is spent on chronic wound care, with costs of treatment for diabetic foot ulcers being up to €60 000 per person per year. Unfortunately, this figure is set to rise in coming years as more of us live longer and the effects of chronic lifestyle-related diseases such as diabetes and obesity take hold.

Control of infection in chronic wounds is key if the right conditions are to be created for these wounds to heal. Neem’s candidate NX-AS-301 is a potential new treatment for this challenging situation. It disrupts communication between the Pseudomonas aeruginosa bacteria that are frequently in the wound and prevents these bacteria from forming the biofilm layer that is crucial in protecting them from current antibiotics being used.

Liver health and weight management
Type 2 diabetes is a well-recognised risk of obesity. It has been described as the largest non-communicable disease in the world. Prediabetes, the condition where blood sugar levels are raised but not sufficiently so as to warrant a diagnosis of Type 2 diabetes, is also related to obesity and is on the rise too. Both of these conditions also carry with them the potential for further damage to liver functioning either as the Type 2 diabetes progresses or as a side effect of the medication prescribed for this disease.

Neem’s NX-CS-201 candidate aims to assist with weight management as a way of reducing the frequency and impact of obesity-related disease symptoms.

This candidate is currently in the early stages of pre-clinical stage development.

 

Human health

Overview
Right now, our human health project pipeline is focused on tackling two significant health challenges of our time – antimicrobial resistance and diseases affecting weight management and liver health.

Respiratory Infections in Cystic Fibrosis
Neem’s lead candidate NX-AS-401 is a potential new treatment for chronic respiratory infections in patients with Cystic Fibrosis. It is designed to help eradicate the Pseudomonas bacteria, which cause the lung infections that are the key source of morbidity and mortality for cystic fibrosis patients.

NX-AS-401 is a quorum sensing inhibitor. It disrupts communication between bacteria, thereby preventing them from forming the film that is crucial in protecting them from current anti-Pseudomonal antibiotics.

Neem’s NX-AS-401 is expected to commence human clinical trials in 2017.

Infection Control in Wounds
Chronic wounds, or those that fail to heal within 12 weeks, are costly both for individuals and societies. This is because of the vicious circle of inflammation, infection and subsequent failure to heal that becomes active when a wound becomes chronic.

Treatment of the direct effects and complications of these wounds accounts for about 3% the NHS’s annual budget. This translates to at least £5000 per patient per year. In Europe, it is estimated that about 4% of the annual healthcare budget is spent on chronic wound care, with costs of treatment for diabetic foot ulcers being up to €60 000 per person per year. Unfortunately, this figure is set to rise in coming years as more of us live longer and the effects of chronic lifestyle-related diseases such as diabetes and obesity take hold.

Control of infection in chronic wounds is key if the right conditions are to be created for these wounds to heal. Neem’s candidate NX-AS-301 is a potential new treatment for this challenging situation. It disrupts communication between the Pseudomonas aeruginosa bacteria that are frequently in the wound and prevents these bacteria from forming the biofilm layer that is crucial in protecting them from current antibiotics being used.

Liver health and weight management
Type 2 diabetes is a well-recognised risk of obesity. It has been described as the largest non-communicable disease in the world. Prediabetes, the condition where blood sugar levels are raised but not sufficiently so as to warrant a diagnosis of Type 2 diabetes, is also related to obesity and is on the rise too. Both of these conditions also carry with them the potential for further damage to liver functioning either as the Type 2 diabetes progresses or as a side effect of the medication prescribed for this disease.

Neem’s NX-CS-201 candidate aims to assist with weight management as a way of reducing the frequency and impact of obesity-related disease symptoms.

This candidate is currently in the early stages of pre-clinical stage development.